Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBITDA (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed EBITDA for 3 consecutive years, with -$20.8 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 25.32% to -$20.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$83.6 million, a 27.08% decrease, with the full-year FY2025 number at -$83.6 million, down 27.08% from a year prior.
  • EBITDA was -$20.8 million for Q4 2025 at Artiva Biotherapeutics, up from -$21.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$11.2 million in Q2 2023 to a low of -$21.4 million in Q3 2025.
  • A 3-year average of -$17.3 million and a median of -$17.6 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 60.7% in 2024, then dropped 18.53% in 2025.
  • Artiva Biotherapeutics' EBITDA stood at -$12.0 million in 2023, then plummeted by 38.47% to -$16.6 million in 2024, then decreased by 25.32% to -$20.8 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's EBITDA are -$20.8 million (Q4 2025), -$21.4 million (Q3 2025), and -$21.3 million (Q2 2025).